Regulatory press release

NET ASSET VALUE – 30 April 2025

On the 30 April 2025 Flerie AB's Net Asset Value (NAV) was SEK 3,965 million and NAV per share was SEK 50.79.

Allocation of NAV	Share of portfolio company	Fair value (MSEK)	Part of NAV per share (SEK)	Share of NAV
Product Development
Prokarium	42%	452	5.80	11.4%
Xspray Pharma	18%	231	2.96	5.8%
Empros Pharma	79%	204	2.62	5.2%
KAHR Medical	31%	182	2.33	4.6%
Lipum	57%	182	2.33	4.6%
Atrogi	37%	176	2.25	4.4%
Xintela	61%	165	2.11	4.1%
Microbiotica	10%	129	1.65	3.2%
Geneos Therapeutics	12%	93	1.19	2.3%
AnaCardio	14%	69	0.89	1.7%
Mendus	24%	60	0.77	1.5%
Toleranzia	53%	60	0.77	1.5%
EpiEndo Pharmaceuticals	9%	54	0.70	1.4%
Synerkine Pharma	43%	54	0.70	1.4%
Vitara Biomedical	11%	48	0.62	1.2%
Buzzard Pharmaceuticals	14%	32	0.40	0.8%
Sixera Pharma	24%	27	0.35	0.7%
Egetis Therapeutics	2%	22	0.28	0.6%
Alder Therapeutics	21%	17	0.22	0.4%
Amarna Therapeutics	58%	11	0.14	0.3%
Strike Pharma	16%	9	0.11	0.2%
Total		2,277	29.17	57.4%

Commercial Growth
Symcel	30%	192	2.46	4.8%
NorthX Biologics	92%	189	2.42	4.8%
Chromafora	30%	73	0.93	1.8%
Nanologica	43%	47	0.61	1.2%
Frontier Biosolutions	2%	18	0.23	0.5%
Bohus Biotech	45%	17	0.21	0.4%
Total		536	6.87	13.5%

Limited Partnerships, total		90	1.15	2.3%

Assets related to Portfolio companies		266	3.41	6.7%
Other assets and liabilities		795	10.18	20.0%

Net asset value		3,965	50.79	100.0%

Flerie in brief
Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com